Welcome to our dedicated page for BOUNDLESS BIO news (Ticker: BOLD), a resource for investors and traders seeking the latest updates and insights on BOUNDLESS BIO stock.
Boundless Bio, Inc. develops clinical-stage oncology therapies aimed at oncogene-amplified tumors through extrachromosomal DNA (ecDNA) biology. Its news centers on BBI-940, an oral, selective Kinesin degrader and ecDNA-directed therapeutic candidate, including KOMODO-1 clinical development, preclinical AACR data, FDA IND acceptance, and cancer-model results.
Company updates also cover financial results, cash runway and capital allocation, conference appearances, and portfolio prioritization, including the discontinued POTENTIATE program that combined BBI-355, a CHK1 inhibitor, with BBI-825, an RNR inhibitor.
Boundless Bio (Nasdaq: BOLD) reported first-quarter 2026 results and program updates on May 8, 2026. Enrollment is ongoing in KOMODO-1, the first-in-human trial of BBI-940 in selected ER+/HER2- and TNBC-LAR breast cancers. AACR 2026 data showed ecDNA reduction and monotherapy tumor regressions in ecDNA+ models. Cash, cash equivalents and short-term investments were $92.8 million as of March 31, 2026, with an expected runway into the second half of 2028.
Q1 operating metrics: R&D $9.7M, G&A $4.7M, and net loss $13.6M.
Boundless Bio (Nasdaq: BOLD) presented preclinical breast cancer data for BBI-940, an oral selective kinesin degrader, at AACR 2026 on April 21, 2026. Findings show genetic and pharmacologic degradation of the novel kinesin caused ecDNA mis-segregation, ecDNA depletion, and reduced viability in ecDNA+ cancer cells.
Key results include 32% sensitivity in breast cancer cell lines, monotherapy tumor regressions in an ecDNA+ TNBC-LAR model, and significant antitumor activity as mono- and combination therapy in an ecDNA+/FGFR1+ ER+ model; BBI-940 is in the Phase 1 KOMODO-1 trial (NCT07408089).
Boundless Bio (Nasdaq: BOLD) will present a poster on its oral Kinesin degrader program at the American Association for Cancer Research Annual Meeting 2026 in San Diego, April 17–22.
The poster covers preclinical work on a novel Kinesin target and the oral degrader BBI-940, which is in the ongoing first‑in‑human KOMODO‑1 trial (NCT07408089) for advanced ER+/HER2‑ and TNBC‑LAR breast cancers. Presentation: April 21, 2026, 2:00–5:00 PM PT, Poster Section 53, Board 18, Abstract LB361.
Boundless Bio (Nasdaq: BOLD) reported Q4 and full-year 2025 results and program updates on March 9, 2026. Key developments: IND for BBI-940 accepted in Jan 2026, KOMODO-1 first-in-human trial is open for enrollment, and POTENTIATE enrollment will cease.
Financials: $107.6M cash as of Dec 31, 2025, runway into the second half of 2028; 2025 net loss $58.2M; R&D $44.8M; G&A $18.7M.
Boundless Bio (Nasdaq: BOLD) announced that President and Chief Executive Officer Zachary Hornby will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida at 11:20 a.m. ET.
A live webcast and archived replay will be accessible via the company’s Investors Events & Presentations page for remote viewing.
Boundless Bio (NASDAQ: BOLD) announced that Zachary Hornby, President and CEO, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 3:00 p.m. ET in New York.
A live and archived webcast will be available in the Investors > Events & Presentations section of the company website.
Boundless Bio (Nasdaq: BOLD) announced FDA acceptance of its IND for BBI-940, a novel Kinesin oral degrader, enabling a first-in-human trial (KOMODO-1) in metastatic breast cancer expected to start in the first half of 2026. The company reported preclinical anti-tumor activity including single-agent tumor regressions in xenograft models and said it expects initial proof-of-concept clinical data within its cash runway. Following portfolio prioritization, Boundless has ceased enrollment in the Phase 1/2 POTENTIATE trial (BBI-355 + BBI-825) and said the revised plan extends its operating runway into the second half of 2028.
Boundless Bio (Nasdaq: BOLD) announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 9:30 a.m. ET in New York, NY.
A live and archived webcast will be available in the Events & Presentations section of Boundless Bio's Investors website.
Boundless Bio (Nasdaq: BOLD) reported third quarter 2025 results and program updates on Nov 5, 2025. The company had $117.6 million in cash, cash equivalents, and short-term investments as of Sept 30, 2025, stated to support operations into the first half of 2028. Enrollment is ongoing in the BBI-355/BBI-825 combination arm of the Phase 1/2 POTENTIATE trial. An IND submission for BBI-940 is on track and a first-in-human Phase 1 trial is expected in the first half of 2026. Q3 2025 results: R&D $10.7M (Q3 2024: $14.1M), G&A $4.5M (Q3 2024: $4.6M), and net loss $13.9M (Q3 2024: $16.5M).
Boundless Bio (Nasdaq: BOLD) announced a poster presentation at the AACR‑NCI‑EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22–26, 2025 in Boston, MA. The poster, titled "Synergistic oral combination of selective RNR inhibitor BBI‑825 with selective CHK1 inhibitor BBI‑355 targets unique dependencies of oncogene amplified cancers", is Abstract Number LB‑A022 in Poster Session A.
The session is scheduled for Thursday, October 23, 2025, 12:30–4:00 PM ET at Level 2, Exhibit Hall D.